Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma - PubMed
3 hours ago
- #EGFR
- #nasopharyngeal carcinoma
- #ADC
- MRG003 is an EGFR-targeted antibody-drug conjugate (ADC) showing significant efficacy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma patients.
- The objective response rate is 42%, with encouraging overall survival, overcoming previous limitations of EGFR therapies.
- MRG003 has a manageable safety profile and exhibits a bystander-killing effect, highlighting ADC potential to revolutionize treatment in this population.